NEW YORK – Carlsbad, California-based company Qualigen Therapeutics Wednesday announced that it had entered into an exclusive license agreement with the University of Louisville (UofL) for the intellectual property rights to UofL's RAS-F family of small molecule drug candidates under development.
The collection of investigational agents includes RAS oncogene protein-protein interaction inhibitor small molecules — that is, agents meant to block the binding of RAS to its effector proteins.